NL-OMON31270尚未招募不适用
The effect of beta-adrenergic receptor blockade on sympathetic activity and coagulation in patients with heart failure (BACH-F study) - BACH-F Study
适应症
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Between 18 and 80 years of age, competent and willing of giving informed consent;
- •2. With stable symptoms of chronic heart failure (NYHA II-III);
- •3. With left ventricular ejection fraction *40%, measured within the previous 6 months; if the ejection fraction is not determined, a left-ventricular end diastolic diameter of greater then 6.0 cm and a fractional shortening of less than 20% as measured by echocardiography;
- •4. With sinusrhythm; (necessary to perform spectral analysis);
- •5. On stable medical therapy with ACE-inhibitors for at least three months, unless contraindicated; otherwise angiotensin receptor blockers (ARBs);
- •6. Already on beta-blocker therapy with maximal tolerated doses;;And healthy subjects between 18 and 80 years of age serve as controls to compare sympathetic and hypercoagulable activity with heart failure patients.
排除标准
- •Excluded are patients
- •1. With a history of adverse reaction on beta-blockers;
- •2. With a contraindication to *-blocker therapy (Sick-sinussyndrome, second and third AV-block), severe hypotension (systolic blood pressure < 100 mm Hg), cardiogenous shock, clinical relevant sinusbradycardia. Asthma, COPD. Liverfunctiondisorder (defined as elevation of aspartamine transaminase, alanine transaminase or bilirubin levels more than three times upper limit of normal range), renal disease (calculated creatinine clearance <50ml/min; using Cockcorft's formula).Insulin dependent diabetes mellitus.);
- •3. With an acute coronary syndrome or myocardial revascularisation within the preceding 3 months;
- •4. Who are using anticoagulant therapy. Aspirin is allowed;
- •5. With severe aortic or mitral valve disease or aortic regurgitation;
- •6. With right ventricle failure;
- •7. Requirement for intravenous inotropic therapy, current treatment with calcium channel blockers (of the diltiazem or verapamil class), amiodaron (>200mg per day) or class-I antiarrhythmic drugs, or administration of any investigational drug in the preceding 30 days.
- •8. Uncontrolled hypertension (blood pressure systolic >170 mmHg or diastolic >105mmHg),
- •9. Symptomatic and sustained ventricular arrhythmias within the preceding two months not adequately treated with antiarrhythmic drugs or without implantation of an automatic defibrillator;
- •10. With implanted pacemaker (necessary for spectral analysis); ICD is allowed
- •11. Pregnancy and women with childbearing potential on inadequate contraception
- •12. Known drug or alcohol misuse
- •13. Poor compliance with treatment
- •14. Any other serious systemic disease that might complicate management and reduce life expectancy.
- •15. With a known allergy for Iodine;Excluded are healthy controls
- •1. Taking any medication that will affect our outcome measurements for at least 2 weeks before entering the study
- •2. With a history of adverse reaction on beta-blockers
- •3. With a contraindication to beta-blocker therapy as described for patients with heart failure
- •4. With pregnancy and women with childbearing potential on inadequate contraception
- •5. Known drug or alcohol misuse
- •6. Known with poor compliance with treatment
研究者
相似试验
进行中（未招募）
不适用
The effect of beta-adrenergic receptor blockade on sympathetic activity and coagulation in patients with heart failure (BACH-F study) - BACH-F studyCongestive heart failureMedDRA version: 9.1Level: LLTClassification code 10010684Term: Congestive heart failureEUCTR2007-001994-27-NLetherlands Heart Foundation80
已完成
不适用
The effect of Beta-Adrenergic receptor blockade on sympathetic activity and Coagulation in patients with Heart failure (BACH-F study).1. Heart failure<br />2. Hemostasis<br />3. Sympathetic activity.NL-OMON21698P.W. Kamphuisen, internist, Vasculair Geneeskundige.80
尚未招募
不适用
The effect of a beta-3 adrenergic receptor agonist on metabolic disease in humans.ACTRN12618001449224Baker Heart and Diabetes Institute60
招募中
不适用
Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctatioaortic coarctation100103941000751010057166hypertensionNL-OMON30486Erasmus MC, Universitair Medisch Centrum Rotterdam20
进行中（未招募）
不适用
Comparison between beta-adrenergic blockers and angiotensin II receptor antagonists for the treatment of late hypertension in patients with repaired aortic coarctation - Treatment of late hypertension in aortic coarctatioEUCTR2006-006861-18-NLDepartment of Cardiology20